Week In Review: 3SBio Inc. To Stage $712 Million Hong Kong IPO

3SBio will seek to raise up to $712 million in its Hong Kong IPO, valuing the company at $2.9 billion; Youbo Pharma was acquired by Jiuzhitang Co., both TCM companies, in a reverse takeover for $1 billion of Jiuzhitang's stock; SciClone Pharma in-licensed greater China rights to Theravance's drug-resistant antibiotic in a $6 million deal; the CFDA sharply raised its review fees for drugs and medical devices, perhaps to hire more reviewers; Cellular Biomedicine, a China-California cell therapy company, reported positive data from a small trial of its Chimeric Antigen Receptor (CAR-T) immunotherapy for lymphoma; and Quintiles opened a new Greater China Regional Headquarters in Shanghai.

Help employers find you! Check out all the jobs and post your resume.